Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
98.24+1.32 (+1.36%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 96.92 |
| Open | 95.76 |
| Bid | 97.50 x 900 |
| Ask | 98.40 x 1300 |
| Day's Range | 95.45 - 98.79 |
| 52 Week Range | 78.06 - 181.83 |
| Volume | 1,413,951 |
| Avg. Volume | 1,757,277 |
| Market Cap | 7.752B |
| Beta (5Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.81 |
| Earnings Date | Feb 24, 2021 - Mar 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 126.95 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Gilead Sciences, Inc.
- Investor's Business Daily
Pfizer Stock 2021: A Lean, Mean, Covid-Fighting Machine?
Pfizer sees coronavirus vaccines as a "durable" business, one executive said recently. But don't expect Pfizer stock to be hung up on Covid-19 in 2021. The company sees plenty of catalysts.
- Zacks
Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
- ACCESSWIRE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT) for violations of the securities laws.
© 2021 Verizon Media. All rights reserved.
